This post was originally published on this site

Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront but that could net the latter up to $770 million in total. Read more.

The post Novartis snaps up neuro partner Cadent for $210M upfront with promise of up to $560M more appeared first on Atlas Venture.